Use of gram negative species to treat atopic dermatitis

Abstract

Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable Gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.

We claim: 
     
         1 . A kit, comprising:
 a) a first container comprising a pharmaceutical composition, wherein the pharmaceutical composition comprises:
 at least one strain of  Roseomonas mucosa , wherein said strain of  Roseomonas mucosa  comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, wherein the at least one strain of  Roseomonas mucosa  is isolated and viable, and wherein the pharmaceutical composition is lyophilized; and 
   b) instructions for reconstituting the pharmaceutical composition for topically applying to skin of a subject.   
     
     
         2 . The kit of  claim 1 , wherein the first container further comprises a pharmaceutically acceptable carrier. 
     
     
         3 . The kit of  claim 2 , wherein the pharmaceutically acceptable carrier comprises sucrose. 
     
     
         4 . The kit of  claim 3 , wherein the pharmaceutically acceptable carrier is sucrose. 
     
     
         5 . The kit of  claim 1 , further comprising a second container. 
     
     
         6 . The kit of  claim 5 , wherein the second container comprises a pharmaceutically acceptable carrier. 
     
     
         7 . The kit of  claim 6 , wherein the pharmaceutically acceptable carrier in the second container comprises a cream, gel, foam, ointment, or liquid. 
     
     
         8 . The kit of  claim 7 , wherein the liquid is water. 
     
     
         9 . The kit of  claim 1 , wherein said strain of  Roseomonas mucosa  is isolated from a subject that does not have atopic dermatitis. 
     
     
         10 . The kit of  claim 1 , wherein the subject is an adult. 
     
     
         11 . The kit of  claim 1 , wherein the subject is a child. 
     
     
         12 . The kit of  claim 1 , wherein the subject is an infant. 
     
     
         13 . The kit of  claim 1 , wherein said strain of  Roseomonas mucosa  comprises the nucleic acid sequence of SEQ ID NO: 10. 
     
     
         14 . The kit of  claim 1 , wherein said strain of  Roseomonas mucosa  comprises the nucleic acid sequence of SEQ ID NO: 11. 
     
     
         15 . The kit of  claim 1 , wherein said strain of  Roseomonas mucosa  comprises the nucleic acid sequence of SEQ ID NO: 12. 
     
     
         16 . The kit of  claim 1 , wherein the at least one strain of  Roseomonas mucosa  comprises a mixture of three strains of  Roseomonas mucosa , wherein each of said strains comprises one of the nucleic acid sequences selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12. 
     
     
         17 . The kit of  claim 1 , wherein the at least one strain of  Roseomonas mucosa  is present in the pharmaceutical composition in a total amount of 10 4  to 10 12  colony forming units. 
     
     
         18 . The kit of  claim 1 , wherein the at least one strain of  Roseomonas mucosa  is present in the pharmaceutical composition in a total amount of about 10 3  colony forming units.